Type(s) of biological therapy-Trastuzumab (Herceptin) Posts on Medivizor
Navigation Menu

Type(s) of biological therapy-Trastuzumab (Herceptin) Posts on Medivizor

Lisinopril versus carvedilol to prevent trastuzumab-related heart problems in patients with breast cancer.

Posted by on Jun 23, 2019 in Breast cancer | 0 comments

In a nutshell This study wanted to find out if lisinopril (Zestril) or carvedilol (Coreg) can help prevent heart problems in patients with HER2 positive breast cancer who are treated with trastuzumab (Herceptin). The study found that both of these medications helped reduce the chance of heart problems in these patients if they were also being...

Read More

Adding anthracyclines or carboplatin to standard treatment of breast cancer

Posted by on Nov 17, 2018 in Breast cancer | 0 comments

In a nutshell This study wanted to find out which medication is better for treating HER-2 positive breast cancer, a class of medicines called anthracyclines plus trastuzmab (Herceptin) and pertuzmab (Perjeta), or carboplatin (Paraplatin) plus trastuzmab and pertuzmab. The study found that both medications worked equally as well as each other, but the...

Read More

Addition of traustuzumab to adjuvant anthracycline and taxane based chemotherapy does not worsen long-term heart function or health related quality of life.

Posted by on Dec 9, 2017 in Breast cancer | 0 comments

In a nutshell This study set out to evaluate heart function in patients who received traustuzumab with anthracycline and taxane–based chemotherapy. This study concluded that, in patients without heart disease at baseline, adding traustuzumab to adjuvant anthracycline and taxane–based...

Read More

ASCO 2017: Breast Cancer Research News

Posted by on Sep 28, 2017 in Breast cancer | 0 comments

Video information: Breast cancer experts gathered at the 2017 American Society of Clinical Oncology meeting to discuss developments in research and treatment. Patient Power founder, Andrew Schorr, was on-site in Chicago and interviewed Dr. Julie Gralow, Director of Breast Medical Oncology at the Seattle Cancer Care Alliance. Dr. Gralow shares...

Read More

The effectiveness and cardiac safety of CMF plus trastuzumab in HER2-positive metastatic breast cancer

Posted by on Apr 13, 2017 in Breast cancer | 0 comments

In a nutshell This study investigated the safety and effectiveness of treatment with combination cyclophosphamide (Cytoxan), methotrexate (Otrexup) and 5-fluoruoracil (Efudex) (CMF) plus trastuzumab (Herceptin) in HER2-positive metastatic breast cancer (MBC, cancer that has spread beyond the breast) patients. CMF plus trastuzumab (CMF+T) was found to...

Read More

How does hormone receptor status affect patient response to trastuzumab therapy in metastatic breast cancer

Posted by on Mar 20, 2017 in Breast cancer | 0 comments

In a nutshell This study investigated the clinical factors that influence patient response to trastuzumab (Herceptin) therapy in human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer (MBC). Hormone receptor (HR) status was found to be a possible predictor of a strong response to trastuzumab-based therapy. Some background...

Read More

Cardiac events after treatment with trastuzumab

Posted by on Feb 29, 2016 in Breast cancer | 0 comments

In a nutshell This study investigated the rate and outcome of trastuzumab (Herceptin) associated cardiac (heart) dysfunction in patients after 1 or 2 years of therapy. The study concluded that for patients treated with adjuvant trastuzamab, the occurrence of cardiac events remained low and that these cardiac events were mostly reversible after...

Read More

Does trastuzumab increase the risk of infection?

Posted by on Aug 9, 2015 in Breast cancer | 0 comments

In a nutshell The authors aimed to determine whether or not the breast cancer treatment trastuzumab (Herceptin) increased the risk of developing certain infections. Some background Human epidermal growth factor receptor positive (HER2+) breast cancers are dependent on the HER2 protein for growth. It is often targeted with a particular...

Read More

Can a trastuzumab-combination chemotherapy treatment cause skin and nail infections?

Posted by on Jul 21, 2015 in Breast cancer | 0 comments

In a nutshell The authors aimed to determine whether severe skin and nail infections observed in patients with breast cancer were due to a combination-chemotherapy treatment. Some background Trastuzumab (Herceptin) is a common drug used to treat patients with human epidermal growth factor 2 positive (HER2+) breast cancer. The HER2 protein can...

Read More

Breast cancer in elderly women; can trastuzumab treatment increase the risk of heart failure?

Posted by on Jun 24, 2015 in Breast cancer | 0 comments

In a nutshell The authors aimed to determine the risks of developing cardiac or heart problems while being treated with trastuzumab (Herceptin) for breast cancer. Some background Trastuzumab is a form of endocrine or hormone therapy used to treat patients with human epidermal growth factor 2 positive (HER2+) breast cancer. Since the approval of...

Read More